Regulation of Bone Remodeling by Parathyroid Hormone
Total Page:16
File Type:pdf, Size:1020Kb
Downloaded from http://perspectivesinmedicine.cshlp.org/ at Harvard Library on March 22, 2018 - Published by Cold Spring Harbor Laboratory Press Regulation of Bone Remodeling by Parathyroid Hormone Marc N. Wein and Henry M. Kronenberg Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Parathyroid hormone (PTH) exerts profound effects on skeletal homeostasis through multiple cellular and molecular mechanisms. Continuous hyperparathyroidism causes net loss of bone mass, despite accelerating bone formation by osteoblasts. Intermittent treatment with PTH analogs represents the only Food and Drug Administration (FDA)-approved bone ana- bolic osteoporosis treatment strategy. Functional PTH receptors are present on cells of the osteoblast lineage, ranging from early skeletal stem cells to matrix-embedded osteocytes. In addition, bone remodeling by osteoclasts liberates latent growth factors present within bone matrix. Here, we will provide an overview of the multiple cellular and molecular mechanisms through which PTH influences bone homeostasis. Notably, net skeletal effects of continuous versus intermittent can differ significantly. Where possible, we will highlight mechanisms through which continuous hyperparathyroidism leads to bone loss, and through which in- termittent hyperparathyroidism boosts bone mass. Given the therapeutic usage of intermittent PTH (iPTH) treatment for osteoporosis, particular attention will be paid toward mechanisms underlying the bone anabolic effects of once daily PTH administration. arathyroid hormone (PTH) is a major also been shown to boost bone mass and reduce Pendocrine regulator of extracellular calcium fractures in patients with osteoporosis when giv- and phosphate levels (Gensure et al. 2005). en by once daily subcutaneous injection (Miller Chronic hyperparathyroidism causes net loss et al. 2016). Currently, iPTH/PTHrP treatments of bone mass caused by excessive stimulation represent the only Food and Drug Administra- www.perspectivesinmedicine.org of bone resorption, but also increases osteoblast tion (FDA)-approved osteoporosis medications numbers and bone formation. In contrast, when that stimulate new bone formation. injected once daily, intermittent PTH (iPTH) It is well documented that iPTH treatment amino acids 1–34 (teriparatide) treatment boosts stimulates new bone formation; however, the bone mass, increases bone formation, and re- cellular and molecular mechanisms through duces fractures in at-risk individuals (Silva et al. which this occurs are incompletely understood. 2011). PTH and parathyroid hormone related In addition, two phenomena may significantly peptide (PTHrP) both signal through the same limit the bone-forming efficacy that these Gprotein–coupled receptor (Juppneret al. 1991). medications achieve. First, iPTH concomitantly Recently, the PTHrP analog, abaloparatide, has stimulates bone formation by osteoblasts and Editors: Gerard Karsenty and David T. Scadden Additional Perspectives on Bone: A Regulator of Physiology available at www.perspectivesinmedicine.org Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved Advanced Online Article. Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031237 1 Downloaded from http://perspectivesinmedicine.cshlp.org/ at Harvard Library on March 22, 2018 - Published by Cold Spring Harbor Laboratory Press M.N. Wein and H.M. Kronenberg bone resorption by osteoclasts (Silva et al. the osteoblast lineage (Fan et al. 2017). Non- 2011). Therefore, concurrent osteoclast stimula- cell-autonomous effects of PTH on osteoblast tion might mitigate some of the gains in bone activity may also occur through increases in mass that are achieved. Second, the ability of actions of growth factors. For example, PTH- iPTH to stimulate new bone formation wanes induced osteoclastic bone resorption may liber- with time and repeated dosing (Finkelstein ate matrix growth factors that in turn recruit et al. 2009). Progressive blunting of the bone osteoblast progenitors to bone surfaces and anabolic effect of iPTH may also limit efficacy stimulate their differentiation (Wu et al. 2010), of prolonged treatment. and PTH increases the production of a variety of These mysteries and limitations associated growth factors by osteoblasts. T lymphocytes in with iPTH therapy highlight the need to achieve the bone marrow microenvironment respond to a precise understanding of the molecular and iPTH by producing cytokines that stimulate cellular mechanisms underlying its effects in osteoblast differentiation (Pacifici 2013). Osteo- bone (Jilka 2007). Over the past three decades, clasts may generate factors important in increas- several cellular mechanisms have been proposed ing osteoblast numbers (Charles and Aliprantis to explain how iPTH treatment increases bone 2014). Finally, through effects on osteocytes, formation (Table 1). PTH treatment increases PTH reduces levels of the antiosteoblastogenic osteoblast cell number among postmitotic cells WNT inhibitor sclerostin (Keller and Kneissel of the lineage in two ways: PTH significantly 2005), thus providing another paracrine mech- decreases osteoblast apoptosis (Jilka et al. 1999) anism through which PTH might stimulate and activates bone lining cells (Kim et al. osteoblast differentiation. The examples listed 2012). Further, PTH acts directly on early cells here represent just the tip of the iceberg of in the osteoblast lineage. Studies on cultured how PTH uses multiple, complementary mech- bone marrow–derived stromal cells (e.g., Ni- anisms to exert its profound influence on bone. shida et al. 1994), and, more recently, in vivo Here, we will dive deeper into these cellular lineage tracing studies (Balani et al. 2017) have mechanisms, highlighting current knowledge shown these effects. PTH also inhibits adipocyte of the intracellular signaling pathways involved, differentiation of early skeletal stem cells in and major unresolved questions. Table 1. Overview of the cellular mechanisms through which PTH promotes bone formation in PTH receptor- expressing cells Target cell Effects of parathyroid hormone www.perspectivesinmedicine.org Skeletal stem cells Increased numbers of Sox9-labeled stem cells owing to reduced apoptosis Increased Runx2 expression and differentiation of leptin receptor-expressing stem cells Bone marrow stromal Inhibits adipocyte differentiation cells Osteoblasts Reduced osteoblast apoptosis Increased WNT signaling in osteoblasts Bone lining cells Direct conversion into bone-forming osteoblasts T lymphocytes Increased WNT10B expression, which promotes osteoblast activity Increased CD40L expression, which increases OPG expression and promotes marrow stromal cells to become osteoblasts Increased IL-17 expression, which stimulates RANKL expression Osteocytes Reduced SOST expression, which enhances osteoblast activity Increased RANKL expression Increased perilacunar/canalicular remodeling See text for details and references. In addition, PTH used several indirect mechanisms to enhance bone formation and promote skeletal remodeling, as summarized in the text. OPG, Osteoprotegerin; IL, interleukin. 2 Advanced Online Article. Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031237 Downloaded from http://perspectivesinmedicine.cshlp.org/ at Harvard Library on March 22, 2018 - Published by Cold Spring Harbor Laboratory Press Bone Remodeling and Parathyroid Hormone OSTEOBLASTS AS PTH TARGETS for osteoblast differentiation and function (Ducy et al. 1997, 1999). Runx2 protein levels Studies in animal models and humans have in vitro and in vivo are tightly controlled by shown that PTH administration leads to in- Nedd4 family HECT ubiquitin ligases (Ingham creased bone formation through an increase et al. 2004), including Smurf1 and WWP1 in osteoblast number and surface, as well as (Zhao et al. 2003; Jones et al. 2006; Shu et al. an increase in mineralized matrix deposition 2013; Wei et al. 2015; Shimazu et al. 2016). In through effects on proliferation of precursors, osteoblasts, PTH signaling promotes Smurf1- suppression of apoptosis, and activation of lin- driven Runx2 ubiquitin-dependent degradation ing cells (Jilka 2007). However, the predominant (Bellido et al. 2003). Therefore, PTH simultane- direct effect of iPTH on osteoblasts in vivo in- ously inhibits osteoblast apoptosis and drives volves reductions in osteoblast apoptosis rather Runx2 degradation; these opposing actions than increased proliferation of preosteoblasts. may explain why iPTH administration is needed Seminal studies (Jilka et al. 1999) in which os- to elicit net effects that favor osteoblast activity. teoblast apoptosis was carefully quantified using In addition to Bad phosphorylation and reg- TUNEL staining on cancellous bone surfaces ulation of Runx2 stability, multiple additional revealed that iPTH treatment reduces osteoblast target genes in osteoblasts have been proposed apoptosis in vivo. Interestingly, in vivo, anti- to contribute to the antiapoptotic effects of apoptotic effects of iPTH are not necessarily iPTH therapy. Transcriptomic profiling of oste- confined to bone-forming osteoblasts; we oblasts treated with PTH or PTHrP identified (Balani et al. 2017) recently showed that iPTH ephrinB2 as a prominently up-regulated gene treatment also reduces apoptosis of Sox9-la- (Allan et al. 2008). Bidirectional ephrin/Eph beled early skeletal stem cells. As described be- signaling regulates